

Oxford Biomedica plc

Questions and Answers

ANNUAL GENERAL MEETING
held at the offices of Oxford Biomedica
on 27 May 2022 at 3.00 p.m.

Oxford Biomedica plc

ANNUAL GENERAL MEETING

Questions and Answers

Any questions answered on the day, sent to us during the meeting or via email in advance of the meeting are outlined below.

Q Could you talk a little bit in broad terms about the synergies and the efficiency gains that we can make from our expertise in lenti transferring that to the AAV field and perhaps vice versa, the expertise in the AAV side that we're going to be gaining from Boston?

A. We would note that in our results presentation our Chief Scientific Officer presented a slide which addressed technical synergies.

In addition, one of the key synergies when we did the deal [with Homology Medicines] was when you look at the offering on the Boston side, their expertise is in process development, clinical manufacture and analytics. What we can provide as a synergy here in Oxford is a commercial supply solution. We can make at scale commercially near/commercially ready AAV products and it can flow through the Boston site and into Oxford. We have a commercially approved facility ready to go so we can offer lenti end-to-end processing (with fill/finish) and now we can offer the same for AAV. Customers can come to us with their gene of interest, to our plug and play platform in Boston, with clinical development and analytics design. And if customers need commercial supply we already have an FDA approved facility in Oxford ready to go. So it really is an end-to-end offering for cell and gene therapy whether that be AAV or lenti.